---
title: "RVL Pharmaceuticals plc (RVLPQ.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/RVLPQ.US.md"
symbol: "RVLPQ.US"
name: "RVL Pharmaceuticals plc"
industry: "制药"
---

# RVL Pharmaceuticals plc (RVLPQ.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.rvlpharma.com](https://www.rvlpharma.com) |

## Company Profile

RVL Pharmaceuticals Plc 专注于神经学和妇女健康产品的开发和商业化。其产品包括 Upneeq、M-72、Arbaclofen ER、OS870、Divigel、OB Complete、Methylphenidate ER、Venlafaxine ER tablets (VERT)、Hydromorphone ER、Sodium Benzoate/Sodium Phenylacetate、Oxybutynin ER、Prescription Prenatal Vitamins、Chlorzoxazone (Lorzone AG)、Tramadol ER (ConZip AG...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-24T04:30:13.000Z

**Overall: D (0.68)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 181 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.64% |  |
| Net Profit YoY | -20.81% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 111.41 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 36.92M |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -182.44% | E |
| Profit Margin | -184.91% | E |
| Gross Margin | 76.43% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.64% | C |
| Net Profit YoY | -20.81% | D |
| Total Assets YoY | -31.58% | E |
| Net Assets YoY | -72.10% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -54.08% | D |
| OCF YoY | 5.64% | C |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.35 | D |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 80.88% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - RVL Pharmaceuticals plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-182.44%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-184.91%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "76.43%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.64%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-20.81%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-31.58%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-72.10%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-54.08%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "5.64%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "80.88%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2023-10-27T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

## References

- [Company Overview](https://longbridge.com/en/quote/RVLPQ.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/RVLPQ.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/RVLPQ.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.